AstraZeneca Hong Kong President Sian Ng On The Pros And Cons Of The Hong Kong Market: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Hong Kong is increasingly viewed, and judged, in the shadow of Mainland China, which has seen explosive growth in recent years and has become the top emerging markets priority for most Big Pharma. This perception, however, obscures the reality that Hong Kong remains an independent and vibrant market, where new drugs are often approved more quickly than on the mainland.